Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is still a top stock to buy at many Wall Street firms, and some consider it a potential acquisition target. Some analysts see likely strong accretive near-term to an acquirer, given the very impressive $1.5 billion revenues, which are big enough to be significant to a larger company. The Thomson/First Call estimate is posted at $189.67. Alexion closed Friday $159.79, down a staggering 8%.Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares after opening at $159.67 moved to $159.88 on last trade day and at the end of the day closed at $149.76. Company price to sales ratio in past twelve months was calculated as 19.17 and price to cash ratio as 19.63.FireEye Inc (NASDAQ:FEYE) showed a negative weekly performance of -15.86%.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the sector hard. The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund was down a whopping 4.4% on Friday. After the vicious sell-off, some of the major firms on Wall Street say that this is a perfect entry point for some of the top biotechnology stocks to buy. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) shares fell -2.76% in last trading session and ended the day on $239.23. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) yearly performance is 53.32%.
Under the results published on Mar. 20 by the Federal Reserve, under the hypothetical severely adverse economic stress scenario in the Dodd-Frank Act Stress Test (DFAST) run by the Federal Reserve, Zions’ capital ratios would not have met the minimum requirements under the Federal Reserve’s capital adequacy rules. Zions announced that, based upon an initial review of the Federal Reserve’s publication, Zions’ DFAST results were worse than Zions had projected primarily because of the following factors: 1)Significantly higher commercial real estate losses; 2)Significantly greater risk-weighted assets, and 3) Lower pre-tax, pre-provision net revenue. Zions Bancorporation (NASDAQ:ZION) shares moved down -2.98% in last trading session and was closed at $30.31, while trading in range of $30.13-$31.51.Zions Bancorporation (NASDAQ:ZION) year to date performance is 1.30%.
Endocyte, Inc. (NASDAQ:ECYT) was soaked in a lot of positive news last week. First, the company announced positive mid-stage trial results for its lung cancer drug Vynfinit, raising hopes on the company’s pipeline. Also, the European Union regulators recommended adoption of Vynfinit for the treatment of ovarian cancer. Endocyte, Inc. (NASDAQ:ECYT) weekly performance is 95.97%. On last trading day company shares ended up $27.22. Endocyte, Inc. (NASDAQ:ECYT) distance from 50-day simple moving average is 99.83%. Analysts mean target price for the company is $20.56.